Journey Medical Shares Retreat After Annual Revenue Misses Wall Street's Estimate

Dow Jones

03/26

By Elias Schisgall

Shares of Journey Medical fell after the company reported 2025 revenue that missed Wall Street's expectations due to falling sales for Accutane, treatment for severe cases of acne

The stock was down 7.7% to $6.30 in post-market trading on Wednesday, falling deeper into negative territory after closing the regular trading session off by 1.2%. Shares are up 5.4% in the past year.

The commercial-stage pharmaceutical company reported a full-year loss of $11.4 million, or 47 cents a share, compared with a loss of $14.7 million, or 72 cents a share, in 2024.

Revenue rose to $61.9 million, up from $56.1 million in 2024. Analysts polled by FactSet were expecting $64.6 million in revenue.

Growth in revenue was driven by inaugural sales for and the commercialization of Emrosi. That was offset by competitive pressures on Accutane revenue, which fell by $6.5 million.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

March 25, 2026 18:09 ET (22:09 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2622000415"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622000415\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622000415?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 06:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622000415","market":"us","top_or_hot":-1,"title":"Journey Medical Shares Retreat After Annual Revenue Misses Wall Street's Estimate","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Journey Medical fell after the company reported 2025 revenue that missed Wall Street's expectations due to falling sales for Accutane, treatment for severe cases of acne \n</p>\n<p>\n  The stock was down 7.7% to $6.30 in post-market trading on Wednesday, falling deeper into negative territory after closing the regular trading session off by 1.2%. Shares are up 5.4% in the past year. \n</p>\n<p>\n  The commercial-stage pharmaceutical company reported a full-year loss of $11.4 million, or 47 cents a share, compared with a loss of $14.7 million, or 72 cents a share, in 2024. \n</p>\n<p>\n  Revenue rose to $61.9 million, up from $56.1 million in 2024. Analysts polled by FactSet were expecting $64.6 million in revenue. \n</p>\n<p>\n  Growth in revenue was driven by inaugural sales for and the commercialization of Emrosi. That was offset by competitive pressures on Accutane revenue, which fell by $6.5 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 25, 2026 18:09 ET (22:09 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Journey Medical Shares Retreat After Annual Revenue Misses Wall Street's Estimate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJourney Medical Shares Retreat After Annual Revenue Misses Wall Street's Estimate\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-03-26 06:09</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Journey Medical fell after the company reported 2025 revenue that missed Wall Street's expectations due to falling sales for Accutane, treatment for severe cases of acne \n</p>\n<p>\n  The stock was down 7.7% to $6.30 in post-market trading on Wednesday, falling deeper into negative territory after closing the regular trading session off by 1.2%. Shares are up 5.4% in the past year. \n</p>\n<p>\n  The commercial-stage pharmaceutical company reported a full-year loss of $11.4 million, or 47 cents a share, compared with a loss of $14.7 million, or 72 cents a share, in 2024. \n</p>\n<p>\n  Revenue rose to $61.9 million, up from $56.1 million in 2024. Analysts polled by FactSet were expecting $64.6 million in revenue. \n</p>\n<p>\n  Growth in revenue was driven by inaugural sales for and the commercialization of Emrosi. That was offset by competitive pressures on Accutane revenue, which fell by $6.5 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 25, 2026 18:09 ET (22:09 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DERM","symbol_name":"Journey Medical Corp","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2622000415","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622000415","pubTimestamp":1774476540,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Journey Medical fell after the company reported 2025 revenue that missed Wall Street's expectations due to falling sales for Accutane, treatment for severe cases of acne. The stock was down 7.7% to $6.30 in post-market trading on Wednesday, falling deeper into negative territory after closing the regular trading session off by 1.2%. Shares are up 5.4% in the past year.The commercial-stage pharmaceutical company reported a full-year loss of $11.4 million, or 47 cents a share, compared with a loss of $14.7 million, or 72 cents a share, in 2024.Revenue rose to $61.9 million, up from $56.1 million in 2024. Analysts polled by FactSet were expecting $64.6 million in revenue.Growth in revenue was driven by inaugural sales for and the commercialization of Emrosi. That was offset by competitive pressures on Accutane revenue, which fell by $6.5 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"DERM":"Journey Medical Corp"},"translate_title":"年收入低于华尔街预期后，Journey Medical股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DERM":1.5},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Shares of Journey Medical fell after the company reported 2025 revenue that missed Wall Street's expectations due to falling sales for Accutane, treatment for severe cases of acne \n\n\n  The stock was down 7.7% to $6.30 in post-market trading on Wednesday, falling deeper into negative territory after closing the regular trading session off by 1.2%. Shares are up 5.4% in the past year. \n\n\n  The commercial-stage pharmaceutical company reported a full-year loss of $11.4 million, or 47 cents a share, compared with a loss of $14.7 million, or 72 cents a share, in 2024. \n\n\n  Revenue rose to $61.9 million, up from $56.1 million in 2024. Analysts polled by FactSet were expecting $64.6 million in revenue. \n\n\n  Growth in revenue was driven by inaugural sales for and the commercialization of Emrosi. That was offset by competitive pressures on Accutane revenue, which fell by $6.5 million. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 25, 2026 18:09 ET (22:09 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}